A detailed history of Verition Fund Management LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 60,871 shares of TVTX stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,871
Previous 28,288 115.18%
Holding current value
$1.15 Million
Previous $232,000 266.81%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.89 - $15.21 $257,079 - $495,587
32,583 Added 115.18%
60,871 $851,000
Q2 2024

Aug 14, 2024

BUY
$5.26 - $8.28 $148,794 - $234,224
28,288 New
28,288 $232,000
Q2 2023

Aug 14, 2023

BUY
$15.3 - $22.61 $153,765 - $227,230
10,050 New
10,050 $154,000

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.21B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.